Press Releases Presented at SLEEP 2010: Somnus Therapeutics Developing Medication to Prevent Middle-of-the-Night Awakening With No Adverse Effects on Next Day Performance – June 9, 2010 Somnus Therapeutics Closes US$15 Million Series A Financing with CTI Life Sciences and Care Capital Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening - June 8, 2009 Somnus Therapeutics Completes Phase I Study of Sleep Maintenance Drug - December 10, 2008 Somnus Therapeutics, Inc. Introduces its Scientific Advisory Board – November 5, 2008 Somnus Therapeutics, Inc. Somnus Therapeutics, Inc. Announces Initial Board of Directors – September 16, 2008 Somnus Therapeutics, Inc. Announces CEO and Formation of Executive Development Team – May 22, 2008
Press Releases
Presented at SLEEP 2010: Somnus Therapeutics Developing Medication to Prevent Middle-of-the-Night Awakening With No Adverse Effects on Next Day Performance – June 9, 2010 Somnus Therapeutics Closes US$15 Million Series A Financing with CTI Life Sciences and Care Capital Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening - June 8, 2009 Somnus Therapeutics Completes Phase I Study of Sleep Maintenance Drug - December 10, 2008 Somnus Therapeutics, Inc. Introduces its Scientific Advisory Board – November 5, 2008 Somnus Therapeutics, Inc. Somnus Therapeutics, Inc. Announces Initial Board of Directors – September 16, 2008 Somnus Therapeutics, Inc. Announces CEO and Formation of Executive Development Team – May 22, 2008
